The Bioproduction market value is expected to reach US$ 63,393.93 million by 2030 from US$ 22,337.24million in 2022.

The report highlights trends occurring in the market and factors driving and hindering the growth of the bioproduction market.

Automation can deliver many benefits for cell therapy developers, including reduced risk of contamination, improved consistency, and reduced cost of production. Many companies have offered devices to enable automation, such as the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi, which are designed to enable the automation of most successive unit operations for a CAR-T process within a single system. A rising number of cell therapies have shifted the production of cell therapy goods from a small volume to a large volume worldwide. In addition, the evolution of cell therapy, from an academic and clinical setting to mass production and commercialization is increasing the demand for automation in manufacturing. Increasing research activities in cell therapies have led to a rise in demand for advanced manufacturing solutions. In view of this, many players are offering products to meet the digital needs of academic researchers and large biotechnology companies. For instance, in May 2019, GE Healthcare launched the Chronicle web application to support the complete cell therapy workflow. Chronicle automation software is a good manufacturing practice (GMP)- a compliant digital solution designed to optimize complex cell therapy process development and manufacturing.

Companies are also entering into strategic and technological developments for automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the fitness of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software) along with reagents, consumables, and instruments. In March 2019, Lonza partnered with Israel's Sheba Medical Center to provide automated and closed CAR-T manufacturing using its point-of-care Cocoon cell therapy manufacturing platform. Thus, the increasing adoption of automation among cell therapy manufacturers is anticipated to drive the market.

The bioproduction market, by product, is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest market share in 2022. The cell and gene therapies segment is estimated to register the highest CAGR in the market from 2022 to 2030. Cell therapy and gene therapy are the overlapping fields in biomedical treatment and research. Both therapies aim to prevent, treat, or potentially cure diseases.

Moreover, both therapies can improve the underlying cause of genetic and acquired diseases. Cell therapy intends to treat diseases by restoring or modifying several sets of cells outside the body before being injected into the patient or by using cells to carry a therapy across the body. Gene therapy aims to treat diseases by restoring or introducing new genes into cells-either outside of the body (ex vivo) or inside the body (in vivo). The gene therapies work by adjusting genes in specific types of cells and incorporating them into the body.

The bioproduction market, by equipment, is segmented into consumables and accessories, downstream equipment, bioreactors, and upstream equipment. The consumables and accessories segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR of 14.7% in the market during 2022-2030. Bioproduction involves utilizing various consumables and accessories, such as cells, reagents, enzymes, and growth mediums. It also requires disposable glassware and plastic ware such as petri dishes, test tubes, pipettes, automated pipette tips, and beakers. All the products mentioned above are known as consumables. Consumables are used at every step of the cell therapy manufacturing process. They are also required at the time of the quality control (QC) process to ensure appropriate quality testing. Continuous research and developments in the biopharmaceutical industry are likely to demand more consumables and accessories in the coming years. These are also demanded in greater quantities as, most of the time, consumables are used for trial-and-error processes.

The bioproduction market, by end-users, is segmented into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest share of the market in 2022. However, contract manufacturing organizations are anticipated to register the highest CAGR of 14.7% in the market from 2022 to 2030. A contract research organization (CRO) presents support services to biotechnology, pharmaceutical, and medical device companies throughout product development. CROs specialize in research and bring value to pharmaceutical and biotechnology companies by saving them infrastructure and R&D facility costs, as well as reducing the time involved in conducting clinical trials. These organizations require various services for detecting specific diagnosing of diseases, mapping genes, and identifying novel oncogenes or genetic aberrations contributing to various cancers.

United States Food and Drug Administration (USFDA), Institute for Clinical and Economic Review (ICER), and Centers for Disease Control and Prevention (CDC) are a few key primary and secondary sources mentioned while preparing the report on the bioproduction market.